HUYA And TIPR Join Forces To Advance Medical Innovation

HUYA Bioscience International and Tianjin Institute of Pharmaceutical Research (TIPR) announced that the companies have entered into a joint venture to develop both Chinese and western medical technologies for the global market.

As part of their joint venture agreement, HUYA and TIPR will have an equal part in taking the lead for product development and marketing. The partnership will be known as TIPR-HUYA Advancing Innovative Medicines (TIPR-HUYA-AIM) and will initially focus on the rapidly growing Chinese market. TIPR-HUYA-AIM will determine and assess opportunities for medical innovation both inside China’s territories and outside its boundaries. TIPR will contribute use of its infrastructure, while HUYA will leverage its global network to speed the development of potential therapies.

Clement Gingras, HUYA's Chief Technology Officer and COO of HUYA Asia, said, “This partnership is a logical extension of the HUYA business model and an exciting strategic step given the flow of data and knowledge sharing it will create. …We are delighted to join forces to broaden their access to worldwide markets.” Earlier this year, HUYA entered into a similar collaboration with Changzhou Center for Biotech Development (CZCBD) to give innovations from local biopharmaceutical companies a lift into the global market.

Dr. Lida Tang, President of TIPR, said, “The collaboration with HUYA will not only help TIPR progress its current projects in accordance with international standards, but also capitalize on our technical capabilities and infrastructure within China by exploring in-licensing opportunities both in China and in the rest of world.” The partners first signed into a deal in January 2012, which focused on new drug development based on TIPR’s R&D projects. HUYA also inked a deal with Tianjin Research Center of Basic Medical Sciences (TJRCBMS) in the same year.

According to consultancy firm PricewaterhouseCoopers (PwC), China is set to be a bigger player than Europe in the global market for medical technology by 2020, thanks to its efforts to both fuel and employ innovations.